Consun Pharmaceutical Group Limited (HKG:1681)
Hong Kong · Delayed Price · Currency is HKD 14.84
+0.19 (1.30%)
Sep 30, 2026, 4:08 PM HKT
HKG:1681 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,633 | 3,417 | 2,967 | 2,590 | 2,340 | 2,045 | |
Revenue Growth | 11.21% | 15.17% | 14.56% | 10.71% | 14.43% | 16.65% |
Cost of Revenue | 722.95 | 750.24 | 725.13 | 668.44 | 576.74 | 517.32 |
Gross Profit | 2,911 | 2,667 | 2,242 | 1,922 | 1,763 | 1,527 |
Selling, General & Admin | 1,622 | 1,518 | 1,293 | 1,168 | 1,094 | 900 |
Other Operating Expenses | -12.41 | -2.32 | -17.55 | -59.45 | -14.47 | -14.8 |
Operating Expenses | 1,610 | 1,515 | 1,267 | 1,096 | 1,048 | 867.15 |
Operating Income | 1,301 | 1,152 | 974.99 | 825.92 | 715.41 | 660.18 |
Interest Expense | -4.58 | -4.36 | -24.89 | -21.26 | -10.93 | -12.91 |
Interest & Investment Income | 82.93 | 85.28 | 88.3 | 68.92 | 52.41 | 39.25 |
Earnings From Equity Investments | -1.37 | -1.6 | -0.07 | - | - | - |
Currency Exchange Gain (Loss) | -15.63 | -33.03 | -17.88 | -9.03 | -9.28 | 11.33 |
EBT Excluding Unusual Items | 1,362 | 1,198 | 1,020 | 864.55 | 747.61 | 697.85 |
Gain (Loss) on Sale of Assets | -2.76 | -1.93 | -0.35 | -0.85 | -1.22 | -1.99 |
Pretax Income | 1,360 | 1,196 | 1,020 | 863.7 | 746.39 | 695.86 |
Income Tax Expense | 175.1 | 107.29 | 102.73 | 77.15 | 62.7 | 108.74 |
Earnings From Continuing Operations | 1,184 | 1,089 | 917.37 | 786.55 | 683.7 | 587.12 |
Minority Interest in Earnings | -9.35 | -11.07 | -6.92 | -2.02 | -0.79 | 3.06 |
Net Income | 1,175 | 1,078 | 910.46 | 784.53 | 682.91 | 590.17 |
Net Income to Common | 1,175 | 1,078 | 910.46 | 784.53 | 682.91 | 590.17 |
Net Income Growth | 16.46% | 18.41% | 16.05% | 14.88% | 15.71% | 18.32% |
Shares Outstanding (Basic) | 843 | 848 | 821 | 791 | 791 | 802 |
Shares Outstanding (Diluted) | 850 | 855 | 832 | 799 | 792 | 805 |
Shares Change | -0.56% | 2.77% | 4.12% | 0.91% | -1.58% | -1.54% |
EPS (Basic) | 1.39 | 1.27 | 1.11 | 0.99 | 0.86 | 0.74 |
EPS (Diluted) | 1.38 | 1.26 | 1.09 | 0.98 | 0.86 | 0.73 |
EPS Growth | 17.23% | 15.60% | 11.22% | 13.95% | 17.81% | 19.67% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,428 | 1,143 | 977.99 | 766.41 | 896.09 | 627.29 |
Free Cash Flow Per Share | 1.68 | 1.34 | 1.18 | 0.96 | 1.13 | 0.78 |
Dividend Per Share | 0.684 | 0.656 | 0.564 | 0.408 | 0.265 | 0.244 |
Dividend Growth | 16.77% | 16.35% | 38.03% | 53.92% | 8.58% | 3.66% |
Gross Margin | 80.10% | 78.05% | 75.56% | 74.19% | 75.35% | 74.70% |
Operating Margin | 35.80% | 33.71% | 32.86% | 31.89% | 30.58% | 32.29% |
Profit Margin | 32.34% | 31.55% | 30.68% | 30.29% | 29.19% | 28.86% |
Free Cash Flow Margin | 39.30% | 33.46% | 32.96% | 29.59% | 38.30% | 30.68% |
EBITDA | 1,358 | 1,208 | 1,032 | 897.51 | 785.89 | 728.71 |
EBITDA Margin | 37.38% | 35.34% | 34.77% | 34.65% | 33.59% | 35.64% |
D&A For EBITDA | 57.07 | 55.61 | 56.73 | 71.58 | 70.48 | 68.53 |
EBIT | 1,301 | 1,152 | 974.99 | 825.92 | 715.41 | 660.18 |
EBIT Margin | 35.80% | 33.71% | 32.86% | 31.89% | 30.58% | 32.29% |
Effective Tax Rate | 12.88% | 8.97% | 10.07% | 8.93% | 8.40% | 15.63% |